Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know
- 20 May 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 30 (1) , 53-61
Abstract
Tacrolimus has long been the cornerstone of the immunosuppressive standard-of-care in kidney transplantation. Until recently, only an immediate-release formulation of tacrolimus was available in the clinic for twice-daily administration, a schedule that is known to hamper prescription adherence and contributes to the already significant tacrolimus interactions with other drugs and meals. In order to improve patient compliance, two once-daily prolonged-release formulations of tacrolimus have recently been developed and approved. Here we will analyze the main characteristics of these two prolonged-release formulations with the aim to provide practical clinical information for a fully aware drug prescription. Finally, the theoretical advantages of the prolonged-release formulations in terms of prescription adherence, blood level steadiness and drug efficacy and tolerability will be critically reviewed, in order to define the profile of renal recipients who may benefit most from the switch to once-daily tacrolimus.Keywords
This publication has 60 references indexed in Scilit:
- Extended release once a day tacrolimusCurrent Opinion in Organ Transplantation, 2015
- Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT)Transplantation, 2013
- A single daily dose enhances the adherence to immunosuppressive treatment in kidney transplant recipients: a cross-sectional studyClinical and Experimental Nephrology, 2012
- Conversion From Prograf to Advagraf Among Kidney Transplant Recipients Results in Sustained Decrease in Tacrolimus ExposureTransplantation, 2011
- High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantationNephrology Dialysis Transplantation, 2010
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ, 2005
- Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients*1Clinical Pharmacology & Therapeutics, 2004
- Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoringTransplantation, 2004
- Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ TransplantationClinical Pharmacokinetics, 2004
- Mechanisms of Clinically Relevant Drug Interactions Associated with TacrolimusClinical Pharmacokinetics, 2002